340 related articles for article (PubMed ID: 32433778)
1. Protective role of Bruton tyrosine kinase inhibitors in patients with chronic lymphocytic leukaemia and COVID-19.
Thibaud S; Tremblay D; Bhalla S; Zimmerman B; Sigel K; Gabrilove J
Br J Haematol; 2020 Jul; 190(2):e73-e76. PubMed ID: 32433778
[No Abstract] [Full Text] [Related]
2. BTK Inhibitors in Cancer Patients with COVID-19: "The Winner Will be the One Who Controls That Chaos" (Napoleon Bonaparte).
Chong EA; Roeker LE; Shadman M; Davids MS; Schuster SJ; Mato AR
Clin Cancer Res; 2020 Jul; 26(14):3514-3516. PubMed ID: 32345646
[TBL] [Abstract][Full Text] [Related]
3. The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19-infected patients.
Treon SP; Castillo JJ; Skarbnik AP; Soumerai JD; Ghobrial IM; Guerrera ML; Meid K; Yang G
Blood; 2020 May; 135(21):1912-1915. PubMed ID: 32302379
[No Abstract] [Full Text] [Related]
4. CLL and COVID-19 at the Hospital Clinic of Barcelona: an interim report.
Baumann T; Delgado J; Montserrat E
Leukemia; 2020 Jul; 34(7):1954-1956. PubMed ID: 32433507
[No Abstract] [Full Text] [Related]
5. BTK Inhibitors in Chronic Lymphocytic Leukemia.
Gaballa S; Pinilla-Ibarz J
Curr Hematol Malig Rep; 2021 Oct; 16(5):422-432. PubMed ID: 34599723
[TBL] [Abstract][Full Text] [Related]
6. COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus.
Scarfò L; Chatzikonstantinou T; Rigolin GM; Quaresmini G; Motta M; Vitale C; Garcia-Marco JA; Hernández-Rivas JÁ; Mirás F; Baile M; Marquet J; Niemann CU; Reda G; Munir T; Gimeno E; Marchetti M; Quaglia FM; Varettoni M; Delgado J; Iyengar S; Janssens A; Marasca R; Ferrari A; Cuéllar-García C; Itchaki G; Špaček M; De Paoli L; Laurenti L; Levin MD; Lista E; Mauro FR; Šimkovič M; Van Der Spek E; Vandenberghe E; Trentin L; Wasik-Szczepanek E; Ruchlemer R; Bron D; De Paolis MR; Del Poeta G; Farina L; Foglietta M; Gentile M; Herishanu Y; Herold T; Jaksic O; Kater AP; Kersting S; Malerba L; Orsucci L; Popov VM; Sportoletti P; Yassin M; Pocali B; Barna G; Chiarenza A; Dos Santos G; Nikitin E; Andres M; Dimou M; Doubek M; Enrico A; Hakobyan Y; Kalashnikova O; Ortiz Pareja M; Papaioannou M; Rossi D; Shah N; Shrestha A; Stanca O; Stavroyianni N; Strugov V; Tam C; Zdrenghea M; Coscia M; Stamatopoulos K; Rossi G; Rambaldi A; Montserrat E; Foà R; Cuneo A; Ghia P
Leukemia; 2020 Sep; 34(9):2354-2363. PubMed ID: 32647324
[TBL] [Abstract][Full Text] [Related]
7. Outcomes of COVID-19 in patients with CLL: a multicenter international experience.
Mato AR; Roeker LE; Lamanna N; Allan JN; Leslie L; Pagel JM; Patel K; Osterborg A; Wojenski D; Kamdar M; Huntington SF; Davids MS; Brown JR; Antic D; Jacobs R; Ahn IE; Pu J; Isaac KM; Barr PM; Ujjani CS; Geyer MB; Berman E; Zelenetz AD; Malakhov N; Furman RR; Koropsak M; Bailey N; Hanson L; Perini GF; Ma S; Ryan CE; Wiestner A; Portell CA; Shadman M; Chong EA; Brander DM; Sundaram S; Seddon AN; Seymour E; Patel M; Martinez-Calle N; Munir T; Walewska R; Broom A; Walter H; El-Sharkawi D; Parry H; Wilson MR; Patten PEM; Hernández-Rivas JÁ; Miras F; Fernández Escalada N; Ghione P; Nabhan C; Lebowitz S; Bhavsar E; López-Jiménez J; Naya D; Garcia-Marco JA; Skånland SS; Cordoba R; Eyre TA
Blood; 2020 Sep; 136(10):1134-1143. PubMed ID: 32688395
[TBL] [Abstract][Full Text] [Related]
8. Bringing hospital care closer to patients amidst COVID-19.
Cordoba R
Lancet Haematol; 2020 Sep; 7(9):e637. PubMed ID: 32853582
[No Abstract] [Full Text] [Related]
9. Inhibition of Bruton tyrosine kinase in patients with severe COVID-19.
Roschewski M; Lionakis MS; Sharman JP; Roswarski J; Goy A; Monticelli MA; Roshon M; Wrzesinski SH; Desai JV; Zarakas MA; Collen J; Rose K; Hamdy A; Izumi R; Wright GW; Chung KK; Baselga J; Staudt LM; Wilson WH
Sci Immunol; 2020 Jun; 5(48):. PubMed ID: 32503877
[TBL] [Abstract][Full Text] [Related]
10. Oral Bruton tyrosine kinase inhibitors selectively block atherosclerotic plaque-triggered thrombus formation in humans.
Busygina K; Jamasbi J; Seiler T; Deckmyn H; Weber C; Brandl R; Lorenz R; Siess W
Blood; 2018 Jun; 131(24):2605-2616. PubMed ID: 29559479
[TBL] [Abstract][Full Text] [Related]
11. Management of chronic lymphocytic leukemia in Canada during the coronavirus pandemic.
Sehn LH; Kuruvilla P; Christofides A; Stakiw J
Curr Oncol; 2020 Jun; 27(3):e332-e335. PubMed ID: 32669941
[TBL] [Abstract][Full Text] [Related]
12. Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with the BTK inhibitor zanubrutinib: phase 2, single-arm, multicenter study.
Xu W; Yang S; Zhou K; Pan L; Li Z; Zhou J; Gao S; Zhou D; Hu J; Feng R; Huang H; Ji M; Guo H; Huang J; Novotny W; Feng S; Li J
J Hematol Oncol; 2020 May; 13(1):48. PubMed ID: 32393328
[TBL] [Abstract][Full Text] [Related]
13. Bruton's tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia.
Deng J; Isik E; Fernandes SM; Brown JR; Letai A; Davids MS
Leukemia; 2017 Oct; 31(10):2075-2084. PubMed ID: 28111464
[TBL] [Abstract][Full Text] [Related]
14. Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 results.
Byrd JC; Wierda WG; Schuh A; Devereux S; Chaves JM; Brown JR; Hillmen P; Martin P; Awan FT; Stephens DM; Ghia P; Barrientos J; Pagel JM; Woyach JA; Burke K; Covey T; Gulrajani M; Hamdy A; Izumi R; Frigault MM; Patel P; Rothbaum W; Wang MH; O'Brien S; Furman RR
Blood; 2020 Apr; 135(15):1204-1213. PubMed ID: 31876911
[TBL] [Abstract][Full Text] [Related]
15. Clinical and biological implications of target occupancy in CLL treated with the BTK inhibitor acalabrutinib.
Sun C; Nierman P; Kendall EK; Cheung J; Gulrajani M; Herman SEM; Pleyer C; Ahn IE; Stetler-Stevenson M; Yuan CM; Maric I; Gaglione EM; Harris HM; Pittaluga S; Wang MH; Patel P; Farooqui MZH; Izumi R; Hamdy A; Covey T; Wiestner A
Blood; 2020 Jul; 136(1):93-105. PubMed ID: 32202637
[TBL] [Abstract][Full Text] [Related]
16. Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib.
Awan FT; Schuh A; Brown JR; Furman RR; Pagel JM; Hillmen P; Stephens DM; Woyach J; Bibikova E; Charuworn P; Frigault MM; Hamdy A; Izumi R; Linghu B; Patel P; Wang MH; Byrd JC
Blood Adv; 2019 May; 3(9):1553-1562. PubMed ID: 31088809
[TBL] [Abstract][Full Text] [Related]
17. Second-generation inhibitors of Bruton tyrosine kinase.
Wu J; Liu C; Tsui ST; Liu D
J Hematol Oncol; 2016 Sep; 9(1):80. PubMed ID: 27590878
[TBL] [Abstract][Full Text] [Related]
18. ALPINE: zanubrutinib versus ibrutinib in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.
Hillmen P; Brown JR; Eichhorst BF; Lamanna N; O'Brien SM; Qiu L; Salmi T; Hilger J; Wu K; Cohen A; Huang J; Tam CS
Future Oncol; 2020 Apr; 16(10):517-523. PubMed ID: 32207333
[TBL] [Abstract][Full Text] [Related]
19. Clinicopathological characteristics, outcomes and pattern of mutations in patients with follicular lymphoma who progressed on Bruton tyrosine kinase inhibitors.
Jain P; Kanagal-Shamanna R; San Lucas FA; Nastoupil L; Romaguera J; Fayad L; Oki Y; Westin JR; Medeiros LJ; Wang M; Fowler N
Br J Haematol; 2018 Sep; 182(5):718-723. PubMed ID: 28771675
[No Abstract] [Full Text] [Related]
20. Incorporating acalabrutinib, a selective next-generation Bruton tyrosine kinase inhibitor, into clinical practice for the treatment of haematological malignancies.
Danilov AV; Persky DO
Br J Haematol; 2021 Apr; 193(1):15-25. PubMed ID: 33216986
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
